Every Plasma Donation Matters Behind every plasma-derived therapy are thousands of plasma donations. For some rare and chronic conditions, a single patient may rely on hundreds – or even thousands – of plasma donations each year. In Australia, the Australian Red Cross Lifeblood collects plasma from donors and supplies it to CSL Behring to manufacture essential medications. Internationally, CSL Plasma operates 334 plasma donation centres across the U.S., Germany and Hungary, helping ensure a reliable supply of human plasma to manufacture lifesaving medicines for patients worldwide. Manufacturing Plasma-Derived Therapies Starts with Generous Donors By transforming a precious natural resource into innovative therapies, CSL Behring aims to help patients manage chronic conditions, prevent life-threatening complications and live healthier, more fulfilling lives. Through continued investment in plasma collection, manufacturing and scientific innovation, we are working to expand access to these essential medicines and helping meet the growing needs of patients worldwide. Our three state-of-the-art logistics centres in the U.S. and Germany are responsible for receiving, storing and shipping the plasma that is donated at our collection centres. Inventory is controlled by sophisticated logistics software linked to our donor management system. This means we have "vein to vial" control; we can trace each plasma unit from its initial donation, through to laboratory testing, logistics and fractionation – and ultimately, to the product made from the plasma donated. 130 plasma donations are needed to treat one patient with primary immunodeficiency for one year 1,200 plasma donations are needed to treat one patient with severe haemophilia for one year 900 plasma donations are needed to treat one patient with alpha-1 antitrypsin deficiency for one year 1,000 plasma donations are needed to treat one patient with hereditary angioedema for one year CSL IMPACT REPORT 2026 | 13
RkJQdWJsaXNoZXIy MjE2NDg3